http://purl.org/np/RAYpxq5rXvcOhvm_3iwhWAc7I3-UFzibuft686cFeaIC0#Head
http://purl.org/np/RAYpxq5rXvcOhvm_3iwhWAc7I3-UFzibuft686cFeaIC0
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAYpxq5rXvcOhvm_3iwhWAc7I3-UFzibuft686cFeaIC0#assertion
http://purl.org/np/RAYpxq5rXvcOhvm_3iwhWAc7I3-UFzibuft686cFeaIC0
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAYpxq5rXvcOhvm_3iwhWAc7I3-UFzibuft686cFeaIC0#provenance
http://purl.org/np/RAYpxq5rXvcOhvm_3iwhWAc7I3-UFzibuft686cFeaIC0
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAYpxq5rXvcOhvm_3iwhWAc7I3-UFzibuft686cFeaIC0#pubinfo
http://purl.org/np/RAYpxq5rXvcOhvm_3iwhWAc7I3-UFzibuft686cFeaIC0
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAYpxq5rXvcOhvm_3iwhWAc7I3-UFzibuft686cFeaIC0#assertion
http://purl.obolibrary.org/obo/DOID_0090019
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAYpxq5rXvcOhvm_3iwhWAc7I3-UFzibuft686cFeaIC0#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_0090019
http://purl.org/np/RAYpxq5rXvcOhvm_3iwhWAc7I3-UFzibuft686cFeaIC0#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAYpxq5rXvcOhvm_3iwhWAc7I3-UFzibuft686cFeaIC0#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB00973
http://purl.org/np/RAYpxq5rXvcOhvm_3iwhWAc7I3-UFzibuft686cFeaIC0#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAYpxq5rXvcOhvm_3iwhWAc7I3-UFzibuft686cFeaIC0#association
http://www.w3.org/2000/01/rdf-schema#label
therapy with lipid altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate ezetimibe tablets are an inhibitor of intestinal cholesterol and related phytosterol absorption indicated as an adjunct to diet to reduce elevated total c ldl c apo b and non hdl c in patients with primary hyperlipidemia alone or in combination with an hmg coa reductase inhibitor statin 1 1 reduce elevated total c ldl c apo b and non hdl c in patients with mixed hyperlipidemia in combination with fenofibrate 1 1 reduce elevated total c and ldl c in patients with homozygous familial hypercholesterolemia hofh in combination with atorvastatin or simvastatin 1 2 reduce elevated sitosterol and campesterol in patients with homozygous sitosterolemia phytosterolemia 1 3 limitations of use 1 4 the effect of ezetimibe tablets on cardiovascular morbidity and mortality has not been determined ezetimibe tablets have not been studied in fredrickson type i iii iv and v dyslipidemias monotherapy ezetimibe tablets administered alone are indicated as adjunctive therapy to diet for the reduction of elevated total cholesterol total c low density lipoprotein cholesterol ldl c apolipoprotein b apo b and non high density lipoprotein cholesterol non hdl c in patients with primary heterozygous familial and non familial hyperlipidemia combination therapy with hmg coa reductase inhibitors statins ezetimibe tablets administered in combination with a 3 hydroxy 3 methylglutaryl coenzyme a hmg coa reductase inhibitor statin is indicated as adjunctive therapy to diet for the reduction of elevated total c ldl c apo b and non hdl c in patients with primary heterozygous familial and non familial hyperlipidemia combination therapy with fenofibrate ezetimibe tablets administered in combination with fenofibrate are indicated as adjunctive therapy to diet for the reduction of elevated total c ldl c apo b and non hdl c in adult patients with mixed hyperlipidemia ezetimibe tablets administered in combination with fenofibrate are indicated as adjunctive therapy to diet for the reduction of elevated total c ldl c apo b and non hdl c in adult patients with mixed hyperlipidemia the combination of ezetimibe tablets and atorvastatin or simvastatin is indicated for the reduction of elevated total c and ldl c levels in patients with hofh as an adjunct to other lipid lowering treatments e g ldl apheresis or if such treatments are unavailable ezetimibe tablets are indicated as adjunctive therapy to diet for the reduction of elevated sitosterol and campesterol levels in patients with homozygous familial sitosterolemia the effect of ezetimibe tablets on cardiovascular morbidity and mortality has not been determined ezetimibe tablets have not been studied in fredrickson type i iii iv and v dyslipidemias
http://purl.org/np/RAYpxq5rXvcOhvm_3iwhWAc7I3-UFzibuft686cFeaIC0#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RAYpxq5rXvcOhvm_3iwhWAc7I3-UFzibuft686cFeaIC0#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAYpxq5rXvcOhvm_3iwhWAc7I3-UFzibuft686cFeaIC0#association
https://w3id.org/biolink/vocab/relation
https://w3id.org/um/neurodkg/SymptomaticReliefIndication
https://identifiers.org/drugbank:DB00973
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAYpxq5rXvcOhvm_3iwhWAc7I3-UFzibuft686cFeaIC0#provenance
http://purl.org/np/RAYpxq5rXvcOhvm_3iwhWAc7I3-UFzibuft686cFeaIC0#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAYpxq5rXvcOhvm_3iwhWAc7I3-UFzibuft686cFeaIC0#pubinfo
http://purl.org/np/RAYpxq5rXvcOhvm_3iwhWAc7I3-UFzibuft686cFeaIC0#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAYpxq5rXvcOhvm_3iwhWAc7I3-UFzibuft686cFeaIC0#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAYpxq5rXvcOhvm_3iwhWAc7I3-UFzibuft686cFeaIC0#sig
http://purl.org/nanopub/x/hasSignature
K4RgGojoaZEv6cVy9cRyL7/yu5Agl/x5aPTFWNSHeeMaTEJ094bLybVaSC8owx7ZOI8ENw1iq4yWH1D9BGYk+xLN+VGqc22tc2Br4SwK/CwFQdFUDYZe9EbL0WirGZwEv0cqlkH1H4K39rGfzjLZtQctj2hR7wEyvhzuifpFDUE=
http://purl.org/np/RAYpxq5rXvcOhvm_3iwhWAc7I3-UFzibuft686cFeaIC0#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAYpxq5rXvcOhvm_3iwhWAc7I3-UFzibuft686cFeaIC0
http://purl.org/np/RAYpxq5rXvcOhvm_3iwhWAc7I3-UFzibuft686cFeaIC0
http://purl.org/dc/terms/created
2021-07-03T11:44:22.258+02:00
http://purl.org/np/RAYpxq5rXvcOhvm_3iwhWAc7I3-UFzibuft686cFeaIC0
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAYpxq5rXvcOhvm_3iwhWAc7I3-UFzibuft686cFeaIC0
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAYpxq5rXvcOhvm_3iwhWAc7I3-UFzibuft686cFeaIC0
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAYpxq5rXvcOhvm_3iwhWAc7I3-UFzibuft686cFeaIC0
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs